Can a patient with a penicillin allergy receive Cefepime?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

A patient with a penicillin allergy can generally receive Cefepime, as the risk of cross-reactivity is considered negligible, especially since Cefepime has a distinct side chain that is not similar to penicillins 1. When evaluating the safety of administering Cefepime to a patient with a penicillin allergy, it's crucial to consider the potential for cross-reactivity between beta-lactam antibiotics. However, the most recent and highest quality evidence suggests that the risk of cross-reactivity between penicillins and cephalosporins like Cefepime is very low, particularly when the cephalosporin has a dissimilar side chain to the penicillin in question 1. Key points to consider include:

  • The risk of cross-reactivity is negligible (<1%) for cephalosporins with dissimilar side chains to the suspected penicillin 1.
  • Cefepime's side chain is not similar to those of penicillins, suggesting a low risk of cross-reactivity.
  • A thorough review of the patient's allergy history, focusing on reactions to antibiotics, is essential before administering Cefepime.
  • Documenting the nature of previous reactions (e.g., rash, anaphylaxis) is also crucial for safe administration.
  • Cefepime is typically dosed at 1-2 grams every 8-12 hours for most infections, with adjustments needed for renal impairment. Given the low risk of cross-reactivity and the importance of effective antibiotic treatment, Cefepime can be considered a viable option for patients with penicillin allergies, provided that a thorough assessment of their allergy history has been conducted 1.

From the FDA Drug Label

Exercise caution if this product is to be given to penicillin-sensitive patients because cross-hypersensitivity among beta-lactam antibiotics has been clearly documented and may occur in up to 10% of patients with a history of penicillin allergy.

A patient with a penicillin allergy can receive Cefepime, but with caution. The FDA drug label warns of potential cross-hypersensitivity among beta-lactam antibiotics, which may occur in up to 10% of patients with a history of penicillin allergy 2.

From the Research

Patient Allergy Considerations

  • A patient with a penicillin allergy may be able to receive Cefepime, as the cross-reactivity between penicillin and cephalosporins is relatively low, occurring in about 2% of cases 3.
  • The risk of cross-reactivity is higher with first- and second-generation cephalosporins, but newer-generation cephalosporins like Cefepime have a lower risk of cross-reactivity 4.

Cefepime Characteristics

  • Cefepime is a fourth-generation cephalosporin antibiotic with an enhanced antibacterial potency and spectrum 5.
  • It has been shown to be effective in treating various bacterial infections, including those caused by multiply resistant Enterobacter species 5 and Pseudomonas aeruginosa 6.
  • Cefepime can cause side effects, including encephalopathy, especially in elderly patients 7.

Clinical Considerations

  • Clinicians should carefully evaluate a patient's allergy history and consider penicillin skin testing or a graded challenge to determine the risk of an allergic reaction to Cefepime 3, 4.
  • The decision to use Cefepime in a patient with a penicillin allergy should be made on a case-by-case basis, taking into account the patient's individual risk factors and medical history 3, 4.
  • Cefepime has been shown to be safe and effective in the treatment of adult patients with severe infections, including those with nosocomial infections and underlying medical conditions 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1996

Research

Efficacy and safety of cefepime in the treatment of serious bacterial infections in hospitalized adult patients.

Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2000

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.